Media coverage about Aquinox Pharmaceuticals (NASDAQ:AQXP) has been trending positive on Wednesday, Accern Sentiment reports. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aquinox Pharmaceuticals earned a media sentiment score of 0.31 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.1896484204777 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the news headlines that may have impacted Accern’s analysis:
- Aquinox to Present at the 17th Annual Needham Healthcare Conference (finance.yahoo.com)
- Aquinox Pharmaceuticals Inc (AQXP) COO Sells $19,048.26 in Stock (americanbankingnews.com)
- Aquinox Pharmaceuticals (AQXP) Stock Rating Lowered by Zacks Investment Research (americanbankingnews.com)
- Aquinox Pharmaceuticals Inc to Post FY2018 Earnings of ($2.27) Per Share, Cantor Fitzgerald Forecasts (AQXP) (americanbankingnews.com)
- Aquinox Pharmaceuticals Inc (AQXP) to Post FY2019 Earnings of ($1.59) Per Share, Cantor Fitzgerald Forecasts (americanbankingnews.com)
Shares of AQXP stock traded up $0.16 on Wednesday, hitting $14.44. The company’s stock had a trading volume of 39,313 shares, compared to its average volume of 117,140. The firm has a market capitalization of $338.74, a PE ratio of -6.75 and a beta of -14.95. Aquinox Pharmaceuticals has a 12 month low of $10.02 and a 12 month high of $17.42.
A number of equities research analysts have issued reports on the company. Zacks Investment Research lowered Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, March 16th. BidaskClub upgraded Aquinox Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Monday, February 5th. Canaccord Genuity set a $22.00 price target on Aquinox Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, December 11th. Guggenheim started coverage on Aquinox Pharmaceuticals in a research report on Thursday, February 8th. They set a “buy” rating and a $26.00 price objective for the company. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $28.00 price target on shares of Aquinox Pharmaceuticals in a report on Sunday, February 11th. Two analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. Aquinox Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $22.80.
Aquinox Pharmaceuticals Company Profile
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
Receive News & Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.